Pittsburgh University tests artificial livers
This article was originally published in Clinica
Executive Summary
A trial of two HemoCleanse bio-artificial liver systems has begun at the University of Pittsburgh Medical Center. The devices, developed by HemoCleanse and manufactured by Baxter's Perfusion Services, will each be evaluated in five critically-ill patients with encephalopathy who are awaiting liver transplants. Their progress will be compared with patients who receive standard critical care.